Furthermore, among patients whose dose was escalated, the adjusted odds of experiencing the composite adverse outcome of infection, sepsis, or IBD-related hospitalization were higher for those treated with an anti–TNF-α treatment (adalimumab or infliximab) than for those treated with vedolizumab. The gene discussed is TNF; the disease is Sepsis.